Equal-WT
WhaleScore 2.0
?
Affinity Asset Advisors is based out of New York. Affinity Asset Advisors is a hedge fund with 2 clients and discretionary assets under management (AUM) of $553,053,373 (Form ADV from 2024-03-28). Their last reported 13F filing for Q1 2025 included $1,047,782,894 in managed 13F securities
and a top 10 holdings concentration of 55.13%. Affinity Asset Advisors's largest holding is SPDR S&P 500 ETF TRUST with shares held of 400,000. Whalewisdom has at least 19 13F filings, and 15 13G filings
Business Description
Affinity Asset Advisors, LLC ("Affinity"), formed in 2017, is an investment adviser to private fund clients. Founded by Michael Cho and Jonathan Chu, Affinity is a Delaware limited liability company. Michael Cho serves as the Portfolio Manager and has ultimate responsibility for Affinity's management, operations, and investment decisions. Affinity's principal place of business is in New York, New York.
Affinity makes all investment decisions for its Clients' assets, relying on the services of the Portfolio Manager. Investors have no right to participate in the investment of the Clients' assets. The success of the Clients depends largely on the abilities of key individuals. The profitability of the Clients may suffer if any of Affinity's key personnel terminate their relationship with Affinity, die, or become incapacitated. There is no assurance that Affinity will be successful.
Investment Strategy
Affinity may offer any advisory services, engage in any investment strategy, and make any investment considered appropriate, subject to each Client's investment objectives and guidelines. The investment strategies that Affinity pursues are speculative and entail substantial risks, and Clients and Investors should be prepared to bear a substantial loss of capital. There can be no assurance that the investment objectives of any Client will be achieved.
The Funds, through their investments in the Master Fund, pursue an active long-short equity strategy focused on the healthcare sector, generally on pharmaceutical and biotechnology companies that develop, discover, and commercialize drug therapies. The Funds, through the Master Fund, also invest opportunistically across the capital structure, including investments in credit instruments, private transactions, and alternative investments, which may include special purpose acquisition companies. The Clients’ assets may be invested in the securities of a limited number of issuers, emphasizing securities of companies in the healthcare industry and may at times emphasize particular sectors or sub-sectors of that industry.
Owners
- HELLER, DANIEL, BARRY - CHIEF INVESTMENT OFFICER | MEMBER
- CHO, MICHAEL - CO-FOUNDER, MANAGING PARTNER AND PORTFOLIO MANAGER | MANAGING MEMBER
- CHU, JONATHAN, BO-SHING - CO-FOUNDER | MEMBER
- WEINSTEIN, ANDREW, BLAKE - CONTROLLER AND CHIEF COMPLIANCE OFFICER
- NOSKER, PATRICK, LEONARD - DIRECTOR OF RESEARCH | MEMBER Click on the Ownership/Private Fund Data tab for more details.
Known Email Addresses
(Subscription Required)
Other Contact Information
(Subscription Required)
2025-03-31
Top Buys (13F)
| Name | % Change |
|---|---|
| SPY SPDR S&P 500 ETF TRU (PUT) | 21.36% |
| IWM iShares Russell 2000 (PUT) | 5.71% |
| SPY SPDR S&P 500 ETF TRU | 1.6% |
| ALNY Alnylam Pharmaceutic (CALL) | 1.42% |
| TVTX Travere Therapeutics | 1.36% |
2025-03-31
Top Sells (13F)
| Name | % Change |
|---|---|
| XBI SPDR Biotech ETF (PUT) | 5.18% |
| CRNX Crinetics Pharmaceut | 2.67% |
| MESO Mesoblast Ltd (PUT) | 2.23% |
| DEBT-COHE COHERUS BIOSCIENCES (PRN) | 2.17% |
| SYRE Spyre Therapeutics I | 1.83% |
2025-03-31
13F Holdings Summary
| Name | $ Change |
|---|---|
| SPY SPDR S&P 500 ETF TRU(PUT) | 21.36% |
| IWM iShares Russell 2000(PUT) | 5.71% |
| XENE Xenon Pharmaceutical | 4.25% |
| APGE Apogee Therapeutics | 4.1% |
| XBI SPDR Biotech ETF(PUT) | 3.87% |
2025-03-31
13F Activity
| Market Value | $1.05b, Prior: $0.75b |
| Inflows (Outflows) as % of Total MV | +34.047% |
| New Purchases | 33 stocks |
| Added To | 30 stocks |
| Sold out of | 20 stocks |
| Reduced holdings in | 19 stocks |
| Top 10 Holdings % | 55.13% |
| Turnover %[1] | 44.92% |
| Turnover Alt %[2] | 14.78% |
| Time Held Top 20 | 2.7 quarters |
| Time Held Top 10 | 3 quarters |
| Time Held All | 3.53 quarters |
[1]: Turnover is calculated by taking the # of new holdings (initial purchases) + the # of positions sold out of (not just reduced) divided by the total # of holdings for the quarter.
[2]: Alt Turnover is calculated by taking either the total MV of new purchases or the MV of securities sold, whichever is less, divided by the total MV of the fund.
2025-03-31
13F Sector Allocation Over Time
limited to past 4 quarters. Subscribe to see all available data
2025-03-31
Analysis
Top 20 equal-weighted holdings. Performance numbers calculated through 2025-03-31